Epidemiology of psoriasis in hard-to-treat body locations: data from the Danish skin cohort.
Epidemiology
Genital
Hard to treat
Nails
Psoriasis
Journal
BMC dermatology
ISSN: 1471-5945
Titre abrégé: BMC Dermatol
Pays: England
ID NLM: 100968541
Informations de publication
Date de publication:
20 05 2020
20 05 2020
Historique:
received:
08
08
2019
accepted:
10
05
2020
entrez:
22
5
2020
pubmed:
22
5
2020
medline:
12
9
2020
Statut:
epublish
Résumé
Having psoriasis in hard-to-treat areas, i.e. the scalp, face, palms, soles, nails, and genitals, respectively, can impair patients' quality of life. We investigated the prevalence of hard-to-treat body locations of psoriasis, and described patients' clinical and demographic characteristics, and quality of life impacts in a population-based cohort. We performed a cross-sectional study using a total of 4016 adults (≥18 years) with psoriasis from the Danish Skin Cohort. Groups were compared to patients without involvement of hard-to-treat areas. The most frequently affected hard-to-treat area was the scalp (43.0%), followed by the face (29.9%), nails (24.5%), soles (15.6%), genitals (14.1%), and palms (13.7%), respectively. Higher prevalence was generally seen with increasing psoriasis severity. Among all patients 64.8, 42.4, and 21.9% of patients had involvement of ≥1, ≥2, or ≥ 3 hard-to-treat areas. Those with involvement of certain hard-to-treat areas such as hands, feet, and genitals had clinically relevant DLQI impairments. Having involvement of one hard-to-treat area was significantly associated with other hard-to-treat areas affected even after adjusting for age, sex, and psoriasis severity. Psoriasis commonly affects hard-to-treat locations, even in patients with mild disease. For some of these areas, patient-reported disease burden, e.g. as measured by DLQI, is impaired.
Sections du résumé
BACKGROUND
Having psoriasis in hard-to-treat areas, i.e. the scalp, face, palms, soles, nails, and genitals, respectively, can impair patients' quality of life. We investigated the prevalence of hard-to-treat body locations of psoriasis, and described patients' clinical and demographic characteristics, and quality of life impacts in a population-based cohort.
METHODS
We performed a cross-sectional study using a total of 4016 adults (≥18 years) with psoriasis from the Danish Skin Cohort. Groups were compared to patients without involvement of hard-to-treat areas.
RESULTS
The most frequently affected hard-to-treat area was the scalp (43.0%), followed by the face (29.9%), nails (24.5%), soles (15.6%), genitals (14.1%), and palms (13.7%), respectively. Higher prevalence was generally seen with increasing psoriasis severity. Among all patients 64.8, 42.4, and 21.9% of patients had involvement of ≥1, ≥2, or ≥ 3 hard-to-treat areas. Those with involvement of certain hard-to-treat areas such as hands, feet, and genitals had clinically relevant DLQI impairments. Having involvement of one hard-to-treat area was significantly associated with other hard-to-treat areas affected even after adjusting for age, sex, and psoriasis severity.
CONCLUSION
Psoriasis commonly affects hard-to-treat locations, even in patients with mild disease. For some of these areas, patient-reported disease burden, e.g. as measured by DLQI, is impaired.
Identifiants
pubmed: 32434510
doi: 10.1186/s12895-020-00099-7
pii: 10.1186/s12895-020-00099-7
pmc: PMC7238562
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
3Subventions
Organisme : Eli Lilly and Company
ID : NA
Pays : International
Références
J Eur Acad Dermatol Venereol. 2005 Nov;19 Suppl 3:2-6
pubmed: 16274404
Am J Clin Dermatol. 2011 Oct 1;12(5):313-20
pubmed: 21834596
Am J Clin Dermatol. 2001;2(3):159-65
pubmed: 11705093
Br J Dermatol. 2019 Aug;181(2):358-365
pubmed: 30430557
J Dermatolog Treat. 2018 Dec;29(8):754-760
pubmed: 29565190
J Invest Dermatol. 2013 Feb;133(2):377-85
pubmed: 23014338
BMJ Open. 2019 Mar 20;9(3):e028116
pubmed: 30898836
Br J Dermatol. 2016 Jul;175(1):157-62
pubmed: 26852717
J Invest Dermatol. 2005 Mar;124(3):499-504
pubmed: 15737189
Acta Derm Venereol. 2011 Jan;91(1):5-11
pubmed: 20927490
Dermatol Clin. 2000 Jan;18(1):37-46
pubmed: 10626110
J Eur Acad Dermatol Venereol. 2010 Dec;24(12):1425-30
pubmed: 20384688
J Am Acad Dermatol. 2015 Jun;72(6):978-83
pubmed: 25824273
J Am Acad Dermatol. 2018 Jan;78(1):70-80
pubmed: 29102053
J Drugs Dermatol. 2011 Feb;10(2):189-96
pubmed: 21283925
Acta Derm Venereol. 2016 Nov 2;96(7):978-980
pubmed: 27068455
Australas J Dermatol. 2015 Feb;56(1):e18-20
pubmed: 23808667
J Am Acad Dermatol. 2003 Aug;49(2):271-5
pubmed: 12894076
BMC Dermatol. 2018 Jun 28;18(1):4
pubmed: 29954363
Br J Dermatol. 2018 Oct;179(4):844-852
pubmed: 29747232
Arch Dermatol. 2006 Sep;142(9):1190-6
pubmed: 16983006
J Am Acad Dermatol. 2009 Jun;60(6):1024-31
pubmed: 19467374
Indian J Dermatol. 2017 Mar-Apr;62(2):113-122
pubmed: 28400628
Dermatology. 2000;200(4):292-8
pubmed: 10894958
Br J Dermatol. 2019 Mar;180(3):647-656
pubmed: 30188572
Pain. 2011 Oct;152(10):2399-404
pubmed: 21856077
Br J Dermatol. 2013 Jun;168(6):1303-10
pubmed: 23374051
Am J Clin Dermatol. 2016 Aug;17(4):349-58
pubmed: 27113059
Clin Dermatol. 2008 Sep-Oct;26(5):448-59
pubmed: 18755363
J Eur Acad Dermatol Venereol. 2018 Jun;32(6):978-984
pubmed: 29356181
J Am Acad Dermatol. 2007 Jul;57(1):1-27
pubmed: 17572277
Dermatology. 2010;221 Suppl 1:1-5
pubmed: 20733309
J Arthroplasty. 2018 Jul;33(7S):S71-S75.e2
pubmed: 29567002
J Am Acad Dermatol. 2016 Jul;75(1):99-105
pubmed: 27021239
Dermatology. 2015;230(1):27-33
pubmed: 25613671